Financial Status - Atea Pharmaceuticals had $839.7 million in cash and cash equivalents as of September 30, 2021, providing a cash runway through 2025[8] - The 2020 global HCV market was $4.1 billion, with the US accounting for approximately 50% of global DAA sales[40] - Best-in-class combination for Hepatitis C has potential for > $1B[41] COVID-19 - Bemnifosbuvir (AT-527) - Bemnifosbuvir is being developed as a preferred backbone for first combination with protease inhibitors for COVID-19[8] - In a Phase 2 hospitalized study, Bemnifosbuvir 500 mg BID resulted in a -0.7 log10 reduction in viral load vs placebo on Day 2 in high-risk, unvaccinated patients[33, 35] - In the MOONSONG Phase 2 trial, exploratory analyses in high-risk patients showed a potent viral load reduction at Day 3, with Cohort A (550 mg BID) showing -0.3 log10 vs placebo and Cohort B (1,100 mg BID) showing -0.9 log10 vs placebo[36, 37] - Atea plans to initiate a Phase 2/3 combination trial with a protease inhibitor in late 2022[63] Hepatitis C - Bemnifosbuvir & Ruzasvir - Atea has an exclusive worldwide license from Merck for Ruzasvir, a next-generation pan-genotypic NS5A inhibitor[43] - Bemnifosbuvir is approximately 10-fold more active than sofosbuvir in vitro against a panel of laboratory strains and clinical isolates of HCV genotypes 1–5[44] - Atea plans to initiate a bemnifosbuvir + Ruzasvir Phase 2 combination trial in late 2022[63] Dengue - AT-752 - Approximately 400 million people are estimated to be infected with Dengue annually[49, 50] - AT-752 Phase 1 study was completed, showing that AT-752 was well tolerated after either single or multiple doses in healthy subjects[54] - Atea plans to initiate a proof-of-concept program with initial data expected in late 2022[63]

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman & Chief Executive Officer Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President of Legal Conference Call Participants Jonathan Miller - Evercore ISI Tim Lugo - William Blair Roanna Ruiz - SVB Leerink Op ...

Call Start: 16:30 January 1, 0000 5:08 PM ET Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Jonae Barnes - SVP, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO and EVP, Legal John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jonathan Miller - Evercore Lachlan Hanbury-Brown - ...

AT-527 COVID-19 Clinical Development - AT-527 is being evaluated for COVID-19, targeting SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene [8, 9] - Phase 2 study in hospitalized patients demonstrated rapid reduction in viral load leading to viral clearance [13] - Interim results from the global Phase 2 hospitalized study showed a rapid and sustained decrease in viral load in all evaluable patients [26] - In the Phase 2 hospitalized study, 98% of patients sequenced at baseline had the P323L mutation and responded to AT-527 treatment [24] - The company is conducting a global Phase 3 MORNINGSKY trial for COVID-19 in the outpatient setting, with results anticipated in the second half of 2021 [13, 19] AT-752 Dengue Fever Program - Atea is developing AT-752 for the treatment of Dengue Fever, with Phase 1a SAD completed and MAD initiated [60, 63] Financial Status - Collaboration revenue for the three months ended June 30, 2021, was $60391000, compared to $0 in 2020 [71] - Net income per share attributable to common stockholders (basic) for the three months ended June 30, 2021, was $002, compared to $(099) in 2020 [68] - Cash and cash equivalents were $816460000 as of June 30, 2021, compared to $850117000 as of December 31, 2020 [73] - The company had $8165 million in cash and cash equivalents as of June 30, 2021, with cash runway through 2023 [76]

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer and Executive President, Legal John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - J.P. Morgan Matthew Harrison - Morgan Stanley Jonathan Mi ...